AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J's Tremfya to Skyrizi Market Share

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares.

Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was up from $225. The firm highlighted AbbVie’s strong growth momentum and consistent operational execution. The firm downplayed concerns regarding competitive pressure from Tremfya, asserting that it is unlikely to pose a significant threat to Skyrizi’s market dominance.

In Q3 2025, AbbVie Inc. (NYSE:ABBV) reported total net revenues of ~$15.8 billion, representing a 9.10% year-over-year rise. This performance was driven by the explosive growth of newer immunology and neuroscience treatments. The company also earned $1.86 per share, beating estimates by $0.08. The immunology segment remained the company’s powerhouse, generating $7.9 billion in revenue, an 11.2% increase.

This growth was fueled by Skyrizi, which saw sales jump 46% to $4.7 billion, and Rinvoq, which rose 34.1% to ~$2.2 billion. These gains effectively cushioned the decline of Humira, which fell 55.7% to $993 million as biosimilar versions continued to erode its market share. Meanwhile, the oncology sector remained stable with $1.7 billion in revenue, as the growth of newer drugs like Venclexta balanced the impact of price negotiations on Imbruvica.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.